HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight

By Editorial Team

The U.S. Department of Health and Human Services’ general counsel, Mike Stuart, announced on Friday that his office has referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation. This move comes a day after Novo Nordisk A/S threatened litigation over what it described as the telehealth company’s “knockoff” version of its popular weight loss drug Wegovy.

Hims & Hers Health Inc. has found itself in the midst of a legal battle concerning compound drugs, prompting the involvement of federal authorities. The referral to the Department of Justice indicates a significant escalation in the dispute between the companies.

Novo Nordisk A/S raised concerns over the alleged similarities between Hims & Hers’ product and its own, leading to accusations of intellectual property infringement. The involvement of federal agencies suggests that the matter is being taken seriously and could have broader implications for the telehealth industry.

As the investigation unfolds, both companies will need to navigate complex legal issues surrounding intellectual property rights, drug regulations, and competition law. The outcome of this case could set a precedent for how disputes over compound drugs are handled in the future.